NCT04029688: A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in the Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Misc Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: up to 30 Years (Child, Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for Part 1 (single-agent therapy) dose escalation of the study
Exclusions: Patients with symptomatic CNS metastases that result in a neurologically unstable clinical state or require treatment; Patients with prior treatment with a MDM2 antagonist or venetoclax (if eligible for the venetoclax arm of study)

Comments are closed.

Up ↑